Pelacarsen Lowered the Biomarker. It Did Not Save Lives. Now What?
Novartis's pelacarsen, co-developed with Ionis Pharmaceuticals, failed to reduce cardiovascular events despite lowering Lp(a) levels in a Phase 3 trial. The results challenge the Lp(a) targeting thesis and may impact other programs like olpasiran and lepodisiran. Analysts had forecasted $6B in peak annual U.S. sales for pelacarsen.
How this was made
The 30-second read
Why it matters
The trial failure challenges the $6 B market forecast and may delay or cancel further development, affecting both companies' valuations.
Market read
First public disclosure of a major cardiovascular outcomes trial failure; significant for biotech investors.
What to watch
Potential for next‑generation Lp(a) therapies or alternative mechanisms may still sustain long‑term interest.
Background
The article reviews the implications of the failed Phase 3 trial for pelacarsen, a Novartis/ Ionis antisense drug targeting lipoprotein(a).
Ticker impact
Novartis announced the Phase 3 Lp(a)HORIZON trial failed to meet its composite cardiovascular endpoint.
likely downward pressure as investors reassess the drug's commercial potential
The first public disclosure of a pivotal Phase 3 failure for a high‑profile antisense program creates immediate risk for the stock.
Ionis Pharmaceuticals co‑developed pelacarsen and is directly affected by the trial outcome.
potential sell‑off pressure pending market reaction to the trial data
Ionis' pipeline and future collaborations hinge on the perceived success of its antisense technology.
Market effects
Lipid‑lowering biotech sector faces heightened scrutiny; other Lp(a) programs may see valuation pressure.
European and US biotech indices could see modest declines.
Limited to investors in cardiovascular therapeutics and antisense technology.
Counterpoint
Some investors may view the failure as a buying opportunity if the market overreacts.
Key entities
- CompanyNovartis
Pharmaceutical giant and co‑developer of pelacarsen.
- CompanyIonis Pharmaceuticals
ASO technology partner that co‑developed pelacarsen.
